Drug intelligence / Profile preview

APL1101

Development stage: Preclinical
Lead developer: Atransen Pharma
Modality: Small Molecules

Overview

APL1101 is an investigational anti-cancer drug candidate developed by Atransen Pharma. It targets LAT1 (L-type amino acid transporter 1), a membrane protein highly expressed in various cancers and associated with tumor growth and survival. By inhibiting LAT1, APL1101 aims to block the uptake of essential amino acids required for cancer cell proliferation, representing a novel approach to cancer therapy. The drug is being advanced as part of a program focused on "locking inhibition" of amino acid transporters, with the goal of providing new treatment options for certain cancers and refractory diseases[2].

Targets

SLC7A5 (Large neutral amino acid transporter small subunit 1)

Beyond the preview

Go deeper on APL1101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APL1101.

Explore the full profile